W E Evans|M V Relling - JoVE Visualize

Showing results (1-10 of 342) with videos related to

Pageof 35

Sort By:

Science (New York, N.Y.)|October 16, 1999

Pharmacogenomics: translating functional genomics into rational therapeuticsW E Evans, M V Relling

Molecular Pharmacology|May 1, 1990

Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family studyW E Evans, M V Relling

Pharmacogenetics|December 1, 1991

Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizersW E Evans, M V Relling

Pharmacotherapy|September 1, 1996

CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosisJ A Bosso, Q Liu, W E Evans, et al.

Clinical Pharmacology and Therapeutics|March 3, 2007

Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphismT S Jones, W Yang, W E Evans, et al.

Cancer Research|January 1, 1989

Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomesM V Relling, W E Evans, R Fonné-Pfister, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2000

Human cytochrome P450 maximal activities in pediatric versus adult liverJ G Blanco, P L Harrison, W E Evans, et al.

Clinical Pharmacology and Therapeutics|December 1, 1992

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activitiesM V Relling, J S Lin, G D Ayers, et al.

Developmental Pharmacology and Therapeutics|January 1, 1989

Anticancer therapy as a pediatric pharmacodynamic paradigmW E Evans, M V Relling, J H Rodman, et al.

Leukemia|April 14, 2000

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemiaH L McLeod, E Y Krynetski, M V Relling, et al.

Pageof 35

Showing results (1-10 of 342) with videos related to

Sort By:

Pageof 35

Science (New York, N.Y.)|October 16, 1999

Pharmacogenomics: translating functional genomics into rational therapeuticsW E Evans, M V Relling

Molecular Pharmacology|May 1, 1990

Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family studyW E Evans, M V Relling

Pharmacogenetics|December 1, 1991

Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizersW E Evans, M V Relling

Pharmacotherapy|September 1, 1996

CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosisJ A Bosso, Q Liu, W E Evans, et al.

Clinical Pharmacology and Therapeutics|March 3, 2007

Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphismT S Jones, W Yang, W E Evans, et al.

Cancer Research|January 1, 1989

Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomesM V Relling, W E Evans, R Fonné-Pfister, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2000

Human cytochrome P450 maximal activities in pediatric versus adult liverJ G Blanco, P L Harrison, W E Evans, et al.

Clinical Pharmacology and Therapeutics|December 1, 1992

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activitiesM V Relling, J S Lin, G D Ayers, et al.

Developmental Pharmacology and Therapeutics|January 1, 1989

Anticancer therapy as a pediatric pharmacodynamic paradigmW E Evans, M V Relling, J H Rodman, et al.

Leukemia|April 14, 2000

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemiaH L McLeod, E Y Krynetski, M V Relling, et al.

Pageof 35